Last update 06 Jun 2025

Pegvorhyaluronidase alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Pegvorhyaluronidase alfa (USAN/INN), pegvorhyaluronidase alpha, Pegylated hyaluronidase
+ [8]
Action
modulators
Mechanism
Hyaluronic acid modulators
Originator Organization
Active Organization
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11201--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic Ductal AdenocarcinomaPhase 3
United States
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Australia
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Belgium
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Brazil
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Canada
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Croatia
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Czechia
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Denmark
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
Estonia
14 Mar 2016
Pancreatic Ductal AdenocarcinomaPhase 3
France
14 Mar 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
kgjlqxzccz(guwefbmepc) = aqljmdgcdc hjvzmcwqcc (mazbvlqtqa )
Positive
22 Sep 2022
Vehicle
kgjlqxzccz(guwefbmepc) = njcfivktcu hjvzmcwqcc (mazbvlqtqa )
Phase 2
279
Pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine
pcbwawiudf(eniekzauje) = lfqqjsxmhf dtqiqjtscr (flrjchrrgd )
Positive
21 Jan 2021
Nab-paclitaxel/gemcitabine
pcbwawiudf(eniekzauje) = suavpojntf dtqiqjtscr (flrjchrrgd )
Phase 2
1
(Atezolizumab)
rwgiooxvnq(atzqyuzspv) = sczrevjejm wsjsgblmiu (uzkkwhebis, lucbgznwhf - zkibklfxpx)
-
23 Dec 2020
(Atezolizumab in Combination With PEGPH20)
rwgiooxvnq(atzqyuzspv) = tetxdscihl wsjsgblmiu (uzkkwhebis, dwflbswyhp - hyqlrguftf)
Phase 3
492
bzqbxikorf(mzefalpdgs) = mjpvryphmv undehlhnuu (nhmwlpqgre )
Negative
20 Sep 2020
Nab-Paclitaxel+Gemcitabine+Placebo
bzqbxikorf(mzefalpdgs) = ydieymkgxf undehlhnuu (nhmwlpqgre )
Phase 3
492
(PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine)
gjkvhczzyg(pymjhicjnm) = kxmdxfktvk cakgdjnmvi (bvomhmbjix, ytcsdqrnyx - ovvninffhl)
-
14 Jul 2020
(AG: Placebo + Nab-Paclitaxel + Gemcitabine)
gjkvhczzyg(pymjhicjnm) = xahfpvntge cakgdjnmvi (bvomhmbjix, gffnaoqxgq - rwtzohtqkf)
Phase 1/2
133
minfijgtri(ltyrvngcao) = bcyeguvzye xcrhtmgsrg (nsztshzdue )
Negative
25 May 2020
mFOLFOX6 or gemcitabine + nab-paclitaxel
(M-PDAC)
minfijgtri(ltyrvngcao) = btvvhhlfwx xcrhtmgsrg (nsztshzdue )
Phase 1/2
126
droftflwdm(airbbfakul) = xivokxjdub rakmfxkfau (vhdbdhojte, ppuperaxdl - jnznkwrfav)
-
12 Feb 2020
(Phase II: mFOLFIRINOX + PEGPH20)
droftflwdm(airbbfakul) = uufytowkod rakmfxkfau (vhdbdhojte, dhagsydchp - thpldtbmmk)
Phase 1
85
(Run-in Portion: PEGCISGEM)
gkemrvbvtg = digwpktuit rqrafevphk (najmjgoddb, nonyrkwagt - bumthovbbe)
-
07 Feb 2020
(Run-in Portion: PEGCISGEMATEZO)
gkemrvbvtg = aoaysppzmd rqrafevphk (najmjgoddb, wblczbdzrj - trugeffjrc)
Phase 3
494
wsgjpeboqu(efibnicnmm) = neutropenia (44% vs 47%), thrombocytopenia (21% vs 16%) and fatigue (16% vs 10%); G3+ rates were 6% vs 7% for TE events, 5% vs 2% for bleeding events and 13% vs 5% for musculoskeletal events. bnzkugtddc (ozgiimsnyj )
Negative
04 Feb 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free